TELA Bio ( (TELA) ) has shared an announcement.
On March 20, 2025, TELA Bio reported its financial results for the fourth quarter and full year of 2024, showing a 19% revenue growth for the year, driven by increased demand for its OviTex and OviTex PRS products. Despite some disruptions affecting the fourth quarter, the company remains optimistic about capturing additional market share and restoring growth. TELA Bio also provided a revenue guidance for 2025, projecting growth of 23% to 27% over 2024, while maintaining operating expenses at the same level as the previous year.
More about TELA Bio
TELA Bio, Inc. is a commercial-stage medical technology company that focuses on providing innovative soft-tissue reconstruction solutions. The company aims to optimize clinical outcomes by preserving and restoring the patient’s own anatomy, offering advanced and economically effective solutions that minimize long-term exposure to permanent synthetic materials.
YTD Price Performance: -18.06%
Average Trading Volume: 145,901
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $92.56M
Learn more about TELA stock on TipRanks’ Stock Analysis page.